US Stock Insider Trading | Elexis disclosed 2 insider trading transactions on February 20

K-LinePoet · 2026-02-21T19:54:25+00:00

On February 20, 2026, Exelixis disclosed several insider transactions, with Director Jack L. WysZomiERSKI selling nearly 100,000 shares on February 18, and Smith Julie conducting multiple buy and sell transactions on the same day. Exelixis focuses on the development of cancer treatment drugs, and its main candidate drugs are currently under FDA review.

K-LinePoet

2026-02-21 19:54:25

Abstract generation in progress

On February 20, 2026, Exelixis (EXEL) disclosed two insider trading transactions. Director WYSZOMIERSKI JACK L sold 99,600 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Director	WYSZOMIERSKI JACK L	February 18, 2026	Sell	99,600	44.01	4,382,300
February 20, 2026	Director	WYSZOMIERSKI JACK L	February 18, 2026	Buy	20,600	19.77	407,900
February 19, 2026	Director	Smith Julie	February 18, 2026	Sell	44,100	44.50	1,961,900
February 19, 2026	Director	Smith Julie	February 17, 2026	Sell	42,400	43.33	1,838,100
February 19, 2026	Director	Smith Julie	February 18, 2026	Buy	20,000	21.69	434,500
February 19, 2026	Director	Smith Julie	February 18, 2026	Sell	20,000	44.30	887,300
February 19, 2026	Director	Smith Julie	February 17, 2026	Buy	42,400	18.19	771,700
February 19, 2026	Director	Smith Julie	February 18, 2026	Buy	44,100	19.39	854,800
February 18, 2026	Executive	Senner Christopher J.	February 13, 2026	Sell	34,300	43.00	1,474,000
February 18, 2026	Director	MORRISSEY MICHAEL	February 15, 2026	Sell	490,000	43.92	21,520,600

[Company Information]

Exelixis, Inc. is a biotechnology company dedicated to developing small-molecule cancer therapies. The company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc. in November 1994 and changed its name to Exelixis, Inc. in February 2000. The company has launched four marketed drugs, including two formulations of its flagship molecule cabozantinib. Exelixis is actively advancing its product pipeline, with its lead clinical candidate, Zanzalitin, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of colorectal cancer (CRC). The company also has a large late-stage clinical development program aimed at developing additional indications. Through a rational and disciplined investment strategy, Exelixis leverages its internal expertise and strong strategic partnerships to identify and capitalize on opportunities across various scientific fields, including small-molecule drugs and biologics such as antibody-drug conjugates (ADCs).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.